Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates


WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2019.

Minerva has five late-stage clinical efficacy trials ongoing with three product candidates, including a Phase 3 trial with roluperidone (MIN-101) for negative symptoms in patients with schizophrenia, a Phase 2b trial with MIN-117 for major depressive disorder (MDD) associated with anxiety and three Phase 2b trials with seltorexant (MIN-202) for insomnia disorder and MDD. 

“I am very pleased to provide an update and insights into the progress we are making in all of our studies,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.  “We have updated forecast timelines for the roluperidone Phase 3 study and the MIN-117 Phase 2b study, both of which we now expect to read out in the fourth quarter of this year.  

“Our three seltorexant studies will now read out sooner than anticipated, with patient enrollment completed in all three,” said Dr. Luthringer. “We expect to report top-line results from both our first MDD trial and our insomnia trial in the second quarter of 2019, and we expect top-line results from our second MDD trial in the third quarter of 2019.   

“The new timelines reflect the latest information available from our sites, as well as the care that we are taking both in recruiting subjects who meet stringent entry criteria and in engaging well-trained clinical investigators to evaluate the therapeutic benefit of our product candidates,” said Dr. Luthringer.  “I am pleased to report that patient selection to date has met these standards and the investigators are performing well.  Our focus continues to be on trial conduct and data quality.”

Development Updates

Roluperidone (MIN-101):

  • The Company is actively enrolling patients in the pivotal Phase 3 trial with roluperidone ( identifier: NCT03397134).  Approximately 60 sites in the U.S. and Europe are participating in this trial, and target enrollment is approximately 500 patients.  Completion of full enrollment is now expected in the second half of 2019, and top-line results from the 12-week, double-blind portion of the trial are expected in the fourth quarter of 2019.
  • In parallel with advancing its Phase 3 study, Minerva is continuing preparatory work for regulatory filing and commercialization. These activities include clinical pharmacology studies and manufacturing of registration batches.
  • Pre-clinical data presented at the 2019 Congress of the Schizophrenia International Research Society suggest a mechanistic role for roluperidone in addressing negative symptoms. Presenters also indicated the potential of roluperidone for disease modification and improved neuroplasticity.             

Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • Three Phase 2b clinical trials are ongoing with seltorexant, including two in MDD and one in insomnia disorder. 
  • In the first MDD trial, designated as the 2001 trial ( Identifier: NCT03227224), patient enrollment has been completed, with 287 patients enrolled at clinical sites in the U.S., Europe and Japan.  Top-line results from this trial are expected in the second quarter of 2019.
  • Enrollment has also been completed in the insomnia trial, designated as the 2005 trial ( Identifier: NCT03375203), with approximately 360 patients enrolled at clinical sites in the U.S., Europe and Japan. Top-line results are expected in the second quarter of 2019.
  • In the second MDD trial, designated as the 2002 trial ( Identifier NCT03321526), patient enrollment has also been completed, with 100 patients enrolled at clinical sites in the U.S.  Top-line results from this trial are expected in the third quarter of 2019.             


  • A Phase 2b trial is ongoing with MIN-117 to treat patients diagnosed with MDD and associated anxiety disorders ( Identifier: NCT03446846).  Approximately 324 patients are expected to be enrolled at 40 clinical sites in the U.S. and Europe. Completion of enrollment is now expected in the third quarter of 2019, with top-line results expected to be available in the fourth quarter of 2019.             

First Quarter 2019 Financial Results

  • Net Loss:  Net loss was $15.8 million for the first quarter of 2019, or a loss per share of $0.41 (basic and diluted), compared to a net loss of $12.4 million for the first quarter of 2018, or a loss per share of $0.32 (basic and diluted).
  • R&D Expenses: Research and development (R&D) expenses were $11.6 million in the first quarter of 2019, compared to $8.4 million in the first quarter of 2018.  The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. R&D expenses are expected to increase during 2019 with increased patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
  • G&A Expenses: General and administrative (G&A) expenses were $4.7 million in the first quarter of 2019, compared to $4.3 million in the first quarter of 2018. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support the Company’s pre-commercial activities.
  • Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2019 were approximately $79.3 million. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 5697837.

The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit  

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and Exchange Commission on March 6, 2019.  Copies of reports filed with the SEC are posted on our website at  The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

  March 31, December 31,
2019 2018
  (in thousands)
Current Assets:    
Cash and cash equivalents $   30,608   $   50,235  
Marketable securities     48,557       37,763  
Restricted cash     100       100  
Prepaid expenses and other current assets     1,054       1,921  
Total current assets     80,319       90,019  
Marketable securities - noncurrent     -        -   
Equipment, net     29       33  
Other noncurrent assets     15       15  
Operating lease right-of-use assets     371       -   
In-process research and development     34,200       34,200  
Goodwill     14,869       14,869  
Total Assets $   129,803   $   139,136  
Current Liabilities:    
Notes payable $   -    $   -   
Accounts payable     3,026       1,799  
Accrued expenses and other current liabilities     3,721       1,810  
Operating leases     156       -   
Total current liabilities     6,903       3,609  
Long-Term Liabilities:    
Deferred taxes     4,057       4,057  
Deferred revenue     41,176       41,176  
Other noncurrent liabilities     -        29  
Noncurrent operating leases     243       -   
Total liabilities     52,379       48,871  
Stockholders' Equity:    
Common stock     4       4  
Additional paid-in capital     307,800       304,814  
Accumulated deficit     (230,380 )     (214,553 )
Total stockholders' equity     77,424       90,265  
Total Liabilities and Stockholders' Equity $   129,803   $   139,136  

    Three Months Ended March 31,

    (in thousands, except per share amounts)

      2019     2018  
Revenues   $   -    $   -   
Operating expenses:      
Research and development       11,606       8,449  
General and administrative       4,706       4,294  
Total operating expenses       16,312       12,743  
Foreign exchange losses       (6 )     (18 )
Investment income       491       414  
Interest expense       -        (71 )
Loss before income taxes       (15,827 )     (12,418 )
Benefit for income taxes       -        -   
Net (loss) income   $   (15,827 ) $   (12,418 )
Loss per share:      
Basic and diluted   $   (0.41 ) $   (0.32 )
Weighted average shares:      
Basic and diluted       38,968       38,749  


William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

Om GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Governance reform could see African economies benefit to tune of £23bn - PwC Global Economy Watch20.5.2019 12:00:00 CESTPressemelding

Continent-wide analysis of African economies demonstrates positive correlation between economic growth and rising governance indicators Ethiopia and Cote d’Ivoire demonstrate consistent annual average real per-capita growth of >5% since 2013 Particularly strong growth among East African economies (average 3% per capita), while Central Africa has struggled (fall by average 1.3%) Global analysis highlights slowdown in manufacturing sector linked to US-China trade war LONDON, May 20, 2019 (GLOBE NEWSWIRE) -- The latest edition of PwC’s bimonthly Global Economy Watch has found that African economies could receive a windfall of £23bn if each economy applied similar governance reforms equivalent to those made by Cote d’Ivoire since 2013. The continent-wide economic analysis modelled the performance of each country across six of the World Bank’s Worldwide Governance Indicators (2013-17), which covers aspects such as regulatory quality, rule of law and government effectiveness. The analysis ha

Levine Leichtman Capital Partners Promotes Monty Ismail to Senior Associate20.5.2019 11:00:00 CESTPressemelding

LOS ANGELES, May 20, 2019 (GLOBE NEWSWIRE) -- Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, is pleased to announce the promotion of Monty Ismail to Senior Associate. Mr. Ismail joined the London office of Levine Leichtman Capital Partners in 2018. Since that time, he has participated in several successful transactions, including the add-on acquisition of Globe Business Media Group for Law Business Research Ltd. and the recent acquisition of SK AeroSafety. As a dedicated member of the firm’s Structured Equity investment team, he will continue to monitor LLCP portfolio companies as well as be responsible for investment due diligence and analysis of new investment opportunities. “Monty has been an important member of the Levine Leichtman Capital Partners team. He has contributed significantly to the success of our London office and we are excited for his continued growth within the firm,” said Lauren Leichtman, LLCP’s co-founder. For more information

WindSim Names Donna Rennemo Chief Executive Officer20.5.2019 11:00:00 CESTPressemelding

TONSBERG, Norway and WESTLAKE VILLAGE, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- WindSim AS, the leading provider and pioneer of CFD (Computational Fluid Dynamics) based Wind Farm Design Tools (WFDT) utilized for the design of wind farms both onshore and offshore, has today announced that its board of directors has appointed Donna Rennemo as president and chief executive officer. This leadership appointment is effective immediately and follow the Board of Directors in WindSim and John Olaf Rømma agreement to step down as the company’s CEO. “We are fortunate to have someone of Donna Rennemo’s caliber and experience to step up to lead WindSim,” said Dag Honningsvåg, WindSim Chairman of the Board. “We are at a critical moment and we need renewed leadership to successfully implement our strategy and take advantage of the market opportunities ahead. Rennemo is a technology visionary with a proven track record of execution. She is a strong communicator who is customer focused with deep leader

TransCanna Executes LOI To Acquire The Business and Assets of Premier Indoor Cultivator Lyfted Farms20.5.2019 09:05:00 CESTPressemelding

VANCOUVER, British Columbia, May 20, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – TransCanna Holdings Inc. (CSE:TCAN: XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce the execution of a non-binding Letter Of Intent dated May 17, 2019 (the “LOI”) with Lyfted Farms, Inc. (“Lyfted”), of Modesto, California, to acquire the business and assets of Lyfted (the “Proposed Acquisition”). Lyfted Farms is a state licensed producer of high quality indoor grown cannabis. The three permanent state licenses that Lyfted owns are for cultivation (nursery), cultivation (grow), and distribution. “The Proposed Acquisition includes an exceptional brand, with a range of high-end flower, growing revenues, fifty exotic and unique genetic strains and a team that’s been a staple in the Modesto valley with over two decades of cultivating experience. In short, this is another example of an ideal acquisition candidate for TransCanna that offers SKU velocity, growing revenues and branded products that

Fortuna CEO purchases company shares17.5.2019 21:00:00 CESTPressemelding

VANCOUVER, British Columbia, May 17, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that Jorge A. Ganoza, Chief Executive Officer of the Company, has increased his equity position in the Company by acquiring 170,000 common shares on the open market at an average price of US$2.59 per share. An insider report filing reflecting the share acquisition has been made on the SEDI website at About Fortuna Silver Mines Inc. Fortuna is a growth oriented, precious metal producer with its primary assets being the Caylloma silver mine in southern Peru, the San Jose silver-gold mine in Mexico and the Lindero gold Project, currently under construction, in Argentina. The Company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas. For more information, please visit its website at ON BEHALF OF THE COMPANY Carlos Baca Investor Relations Manager Trading symbols: NYSE: FSM | TSX: FVI Inves

Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel17.5.2019 15:25:00 CESTPressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP). Key highlights from the updated guidelines include: Recommendation for TB Screening and Individual Based TB Risk Assessment on Hire : continue baseline screening of all HCPs upon hire with the addition of an individual risk assessment Recommendation to Focus Serial Testing on Higher Risk Individuals: decision to perform TB testing afte